Scleroderma Research Foundation

Analysis

Scleroderma Research Foundation is a registered charity in United States, based in San Francisco, CA. It received its IRS tax-exemption ruling in March 1987, 39 years ago. Its declared purposes cover medical research, which this site groups under health and saving lives. The IRS classifies it as a publicly supported organisation (donations from the general public) under section 501(c)(3), and contributions to it are listed as tax-deductible.

In the financial year ending December 2023, Scleroderma Research Foundation reported income of $8.4m and spending of $6.5m, leaving 23% of income unspent that year. Across the 6 years on record, from April 2019 to December 2023, income grew from $5.2m to $8.4m (+63%), an average of +10% a year. The sharpest change came in the year to December 2022, when income rose by 56%. Over the whole period it spent 74% of the income it received.

Among 40,470 United States charities whose main cause is health and saving lives and that reported income, Scleroderma Research Foundation sits at the 83rd percentile: it is larger than about 83% of them. Against every charity in United States with reported income it ranks in the 94th percentile, and in the 95th percentile within CA. Charities of a similar size with the same main cause include The Little Sisters of the Poor of Indianapolis Inc ($8.4m), Substance Abuse Assessment Center of Kansas ($8.4m) and Wicell Research Institute Inc ($8.4m).

On its Form 990 for the period ending December 2023, revenue came from contributions and grants 47% and program service revenue 46% of the total. Compensation of current officers, directors and key employees was $205k (3.2% of expenses). Other salaries and wages came to $592k. At year end it held assets of $18.7m against liabilities of $7.1m, net assets of $11.5m. It reported 9 employees.